Stent Tek Limited

Life Sciences
Catheter Technology
Aim of funding: 
HMRC Advance Assurance received: 

Stent Tek Limited


The Company is developing a novel catheter system that enables patients to receive haemodialysis (‘HD’) in an improved manner. Currently, patients receiving HD must undergo a surgical procedure to create a surgical connection between an artery and a vein, the vein then acts as a ‘vascular access’ through which a dialysis machine is connected. The surgical connection between the vein and artery is known as an ‘arteriovenous fistula’.  At present, there are more than 2.5 million patients world-wide who require HD due to renal failure. Fistulas, whilst an established technology, are unreliable often blocking up and requiring repeated costly repair operations. In short, the patient’s life is dependent upon dialysis, and the dialysis is dependent upon a fully functioning fistula.

The Company has developed a minimally invasive procedure that uses a ‘stent graft’ (in effect, a synthetic tube) to form the fistula which is then inserted using a proprietary technology named ePATH), a process that is significantly less traumatic than surgery. The resulting fistula is ready in a shorter timeframe and less likely to fail, thus resulting in fewer patients suffering secondary infection and potentially life-threatening medical complications.


The Company has identified a number of potential revenue streams:

  • Direct sales of its ePATH device;
  • Direct sales of its proprietary stent grafts to use in conjunction with the ePATH device;
  • Licensing of intellectual property; and
  • The sale of a defined list of peripherals and replacement parts.

Within the UK, a total of 17,000 people receive HD for kidney failure, with 5,500 people per year starting treatment for kidney failure, of which 40% receive HD.  On a global scale, as of 2012, there was an estimated 3,010,000 end-stage renal dialysis patients, of which approximately 2,358,000 were undergoing HD or peritoneal dialysis and around 652,000 people were living with kidney transplants. More than 50% of the global dialysis patient population is treated in just five countries – the USA, Japan, China, Brazil and Germany.